

## **ALLERGY / IMMUNOLOGY**Infusion Orders

**DHONE** 515 225 2930 | **FAX** 515 559 2495

			FIIONESIS		X 313.333.Z+33
Patient Information		Fax completed form, i	nsurance information and o	clinical documentation	on to 515.559.2495.
Patient Name:			DOB:	Phone:	
Patient Status:	New to Therapy	Continuing Therapy	Next Treatment Date:		
Medical Information					
Patient Weight:	lbs. (required) Allergi	es:			
Therapy Order					
Diagnosis		Infusi	on Orders		Refills
Persistent asthma (ICD-10 Code:)	Xolair 75 mg Sub-C Xolair 150 mg Sub- Xolair 225 mg Sub-	Q	Xolair frequency:		
Chronic idiopathic urticaria (ICD-10 Code:)  Nasal polyps (ICD-10 Code:)	Xolair 375mg Sub- Xolair 450 mg Sub- Xolair 525 mg Sub-	G -G	Every 2 weeks Every 4 weeks		x1 year
Severe asthma with eosinophilic phenotype (ICD-10 Code:) Severe granulomatosis with polyangiitis (ICD-10 Code:)	Cinqair 3 mg/kg IV every 4 weeks Fasenra initial dose: 30 mg Sub-Q every 4 weeks for the first 3 doses, followed by 30 mg Sub-Q every 8 weeks there after Fasenra 30 mg Sub-Q every 8 weeks Nucala 100 mg Sub-Q every 4 weeks Nucala 300 mg Sub-Q every 4 weeks Tezspire 210 mg Sub-Q every 4 weeks			x1 year	
Common variable immunodeficiency (ICD-10 Code:) Other:(ICD-10 Code:)	Immunoglobulin:         IV         Sub-Q          mg/kg OR        gm/kg x        day(s) OR divided overday(s)           Frequency: Every weeks OR          (Hy-Vee Health to choose if not indicated)         Brand:           Additional Ig orders:			x1 year	
Premedication orders: Tylend Di <sub>l</sub>			mine: Cetirizine 10 mg PO Quzytt	tir 10 mg IVP	
Additional premedications:	Solu-Medrol mg	IVP Solu-Cortef	mg IVP Other:		
Lab orders: Required labs to be drawn by:			er:		
Physician Information By signing this form and utiliz designated agent in dealing v	ing our services, you are au	5 5	l its employees to serve as your	prior authorization and	specialty pharmacy
Provider Name:		Signature:		Date:	
Provider NPI:	Phone:	Fax:	Cont	tact Person:	
Opt out of Hy-Vee Health s	electing site of care (if chec	cked, please list site of care):			
Service Areas					
Des Moines, IA West	Des Moines, IA Chica	go, IL Omaha, NE	Buffalo, NY Dallas, TX	Phoenix, AZ Oth	ner



## COMPREHENSIVE SUPPORT FOR ALLERGY / IMMUNOLOGY THERAPY

Patient Information	
Patient Name:	DOB:
Required Documentation for Referral Proces	sing and Insurance Approval
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to co	omplete page 1)
Include patient demographic information and insurance	information
Include patient's medication list	
Supporting clinical notes to include any past tried and/or	r failed therapies, intolerance, benefits or contraindications to conventional therapy
Please indicate any tried and failed therapies (if applic	cable):
Corticosteroids	
Long-acting beta 2 agonist	
Long-acting muscarinic antagonist	
Immunosuppressants (EGPA)	
room visit within a 12-month period? Yes No <i>Asthma</i> – Does the patient have an ACQ score consist	pations requiring a course of oral/systemic corticosteroids, hospitalization or an emergency tently greater than 1.5 or ACT score consistently less than 120? Yes No
PI – Documentation of recurrent bacterial infections, by pneumonococcal vaccine titers	history of failure to respond to antibiotics, documentation of pre and post
Include labs and/or test results to support diagnosis (atta	ach results)
Does patient have a baseline peripheral blood eosinop within 4 weeks (HES)? Yes No	phil level of ≥150 cells/mcL within the past 6 weeks (asthma and EGPA) or ≥1000 cells/mcL
FEV1 score (if applicable):	
Serum IgE level – for asthma and nasal polyps Xolair	
Skin/RAST test – for asthma Xolair	
Serum immunoglobulins – for Ig	
Serum creatinine – for Ig	
CBC w/differential – for Fasenra, Nucala, Cinqair	
If injection order, is the patient or caregiver not compete	ent or physically unable to administer the product for self-administration? Yes No
Xolair – Patient has Epi pen prescribed	
Other Medical Necessity:	

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## HY-VEEHEALTHINFUSION.COM